Sandoz launches an azelastine–fluticasone fixed-dose combination nasal spray in Germany and Switzerland, expanding access to dual-mechanism therapy for allergic rhinitis ahead of the 2026 allergy season.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Sandoz has launched its azelastine‑fluticasone fixed‑dose combination (FDC) nasal spray in Germany and Switzerland, expanding access to a dual‑mechanism therapy for patients with allergic rhinitis ahead of the 2026 allergy season.
The nasal spray combines an intranasal antihistamine (azelastine) with an intranasal corticosteroid (fluticasone) to provide relief from moderate to severe seasonal allergic rhinitis symptoms.
In Germany, the product is available as an over‑the‑counter (OTC) treatment for adults with moderate to severe seasonal allergic rhinitis. It is marketed under the established Lorano brand by Hexal, introducing an innovative azelastine–fluticasone combination nasal spray into the OTC allergy segment and reinforcing Hexal’s position in allergy care.
In Switzerland, the therapy is approved for seasonal allergic rhinitis and rhinoconjunctivitis in patients aged six years and older, as well as for moderate to severe perennial allergic rhinitis and rhinoconjunctivitis in patients aged 12 years and above. The launch expands Sandoz’s antihistamine portfolio with an additional nasal spray treatment option in this key therapeutic area.
“Seasonal allergies can have a real impact on patients, affecting sleep, concentration, productivity, and overall quality of life,” said Christophe Delenta, President Europe at Sandoz. “With the launch of our azelastine/fluticasone combination spray, Sandoz is expanding access for patients in Germany and Switzerland ahead of the 2026 allergy season while also strengthening our position in allergy care.”
Allergic rhinitis affects an estimated 15–20% of the population in Switzerland, equivalent to around two million people, while up to 15 million individuals are affected in Germany. The new therapy provides patients with an additional treatment option comparable to the reference medicine Dymista (Viatris).
The launch also aligns with Sandoz’s broader strategy to capture opportunities arising from an estimated USD 340 billion worth of medicines expected to lose exclusivity globally over the next decade.
Reference
Sandoz launches azelastine/fluticasone nasal spray in Germany and Switzerland, expanding patient access to high-quality allergy treatment option, 23 March 2026, Sandoz launches azelastine/fluticasone nasal spray in Germany and Switzerland, expanding patient access to high-quality allergy treatment option | Sandoz
About the Writer
Chikkula Pavan Kumar, PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.